Drug Profile


Alternative Names: Fesosterodine; Fesoterodine fumarate; PF-00695838; SPM 007; SPM 907; Toviaz

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schwarz Pharma
  • Developer Pfizer
  • Class Antispasmodics; Benzhydryl compounds; Esters; Propionic acids; Small molecules; Urologics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • No development reported Stress incontinence

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Jul 2017 Fesoterodine is still in phase III trials for Overactive bladder (in adolescents, in children) in countries worldwide (PO) (NCT01557244)
  • 01 Jun 2015 Pfizer initiates enrolment in a phase III trial for Overactive bladder (In children, In adolescents) in Japan (NCT02501928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top